Overview:

• Institute of Microbiology under the Chinese Academy of Sciences with Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. as co-developer
• June 19, 2020: approved for phase one
• October 22, 2020: ended phase two
• November 20, 2020: approved for phase three
• Trial started in Xiangtan, Huan Province
• Trials will continue in Uzbekistan, with Indonesia, Pakistan, and Ecuador

Vaccine:

• Adjuvanted recombinant protein subunit (RBD-Dimer) vaccine
• Uses pieces of the SARS-COV2 protein components to trigger a protective immune response
• Induces humoral and a cell-mediated immune response